In accordance with ASX Listing Rule 2.8.2, the Company will apply for quotation of the shares under an Appendix 3B within 10 business days after the end of the escrow period.
View the Release of shares from escrow advisement.
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance
Highlights: Imagion presented results from MagSense® HER2 Phase I study at global breast cancer meeting showing safety and detectability Tasks expert panel of radiologists with
Highlights: Imagion presented prostate cancer research data at World Molecular Imaging Conference (WMIC) Receipt of $2.5 million R&D tax incentive (post-quarter end) MELBOURNE – Imagion
We’re on a mission to make cancer more detectable.